Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice
EP. 1: Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Heather A. Wakelee, MD, FASCO Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.
EP. 2: Real-World Data and Barriers to Use of Molecular Testing in NSCLC
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.
EP. 3: Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.
EP. 4: Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.
EP. 5: Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.
EP. 6: Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.
EP. 7: Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice
EP. 8: Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.
EP. 9: Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.
EP. 10: Selecting Therapy for Advanced NSCLC With EGFR Mutations
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.
EP. 11: Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jonathan Riess, MD,Jessica Donington, MD, MSCR,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.
EP. 12: Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Heather Wakelee, MD,Alexander Spira, MD, PhD, FACP Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.
EP. 13: Novel Therapy for NSCLC With KRAS G12C Mutation
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jonathan Riess, MD,Jessica Donington, MD, MSCR,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.
EP. 14: Novel Therapy for NSCLC With ALK Rearrangements
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.
EP. 15: Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.
EP. 16: Looking Toward the Future Management of Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.
